What stands out for senior leaders
We selected Mayne Pharma Group Limited for a mission with clear human relevance: offering patients better, safe and more accessible medicines. For senior leaders, that purpose makes the connection between patient access and business decisions worth examining.
Reported revenue of A$383.7M in FY2026 and a workforce of 450+ give the business meaningful operating scale. Its ASX listing adds a public-market dimension that we consider relevant to leaders interested in commercial stewardship and governance.
Led by CEO Aaron Gray, Mayne Pharma has offices in Adelaide, Lexington and Raleigh. We see a company worth exploring for leaders drawn to a medicines-focused mission, an established operating footprint and the responsibilities of a publicly listed business.
Leadership areas
- Operations & Strategy
- Finance & Capital
- Legal, Risk & Governance
The honest trade-off
Mayne Pharma may not suit leaders whose preference is for a privately held business rather than an ASX-listed company. Its footprint across Adelaide, Lexington and Raleigh may also be less aligned with those seeking a business based around a single office.
Questions leaders ask about Mayne Pharma Group Limited
- Who leads Mayne Pharma Group Limited?
- Aaron Gray is the CEO of Mayne Pharma Group Limited.
- Where does Mayne Pharma have offices?
- Mayne Pharma has offices in Adelaide, Lexington and Raleigh.
- Is Mayne Pharma publicly listed, and what is its reported revenue?
- Mayne Pharma is publicly listed on the ASX under MYX. Its reported revenue is A$383.7M for FY2026.
Sources
- Mayne Pharma Investor Hub: company overview and headquarters
- Stock Analysis: company profile and incorporation year
- Mayne Pharma 2026 Annual Report
- Australian Financial Review: market capitalisation at 6 November 2026
- About Mayne Pharma: stated purpose
- Mayne Pharma October 2026 investor presentation: global locations
Last checked November 2026


